Intelligence · Clinical Pipeline

Biogen Pipeline

All ClinicalTrials.gov programs at Biogen — phase, modality, and trial IDs.

Programs: 31

Quick answer

Biogen has 31 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

0.9% Saline, PARACETAMOL , Felzartamab, CETIRIZINE , LORATADINE , FAMOTIDINE , DIPHENHYDRAMINE , LEVOCETIRIZINE , DESLORATADINE , FEXOFENADINE , METHYLPREDNISOLONE

Biogen

IgA nephropathy

phase 3 small molecule active

1 trial
BG00012

Biogen

Relapsing-Remitting Multiple Sclerosis

phase 3 small molecule completed

1 trial
BIIB019 (Daclizumab)

Biogen

Relapsing-Remitting Multiple Sclerosis

phase 3 small molecule terminated

1 trial
BIIB059

Biogen

1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus

phase 3 small molecule active

1 trial
BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

Biogen

Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

phase 3 small molecule active

1 trial
BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient

Biogen

systemic lupus erythematosus

phase 3 small molecule active

1 trial
BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient

Biogen

systemic lupus erythematosus

phase 3 small molecule active

1 trial
BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient.

Biogen

Systemic lupus erythematosus

phase 3 small molecule active

1 trial
BIIB067, PL1, Solution for injection, Intrathecal use. [Placebo]

Biogen

Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation

phase 3 small molecule active

1 trial
BIIB111

Biogen

Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP)

phase 3 small molecule active

1 trial
Bardoxolone methyl

Biogen

Pulmonary Hypertension

phase 3 small molecule terminated

1 trial
Felzartamab

Biogen

Immunoglobulin A Nephropathy (IgAN)

phase 3 small molecule active

1 trial
Hard capsules, BIIB141

Biogen

Friedreich’s ataxia

phase 3 small molecule active

1 trial
Placebo

Biogen

Multiple Sclerosis, Remittent Progressive

phase 3 small molecule completed

1 trial
Plegridy 125 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5ml solution for injection in pre-filled pen., Plegridy 63 micrograms+94 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5 ml solution for injection.

Biogen

Relapsing Remitting Multiple Sclerosis (RRMS)

phase 3 small molecule active

1 trial
SPINRAZA 28 mg, SPINRAZA 50 mg

Biogen

Spinal Muscular Atrophy

phase 3 small molecule active

1 trial
SPINRAZA 50 mg, SPINRAZA 28 mg

Biogen

Spinal Muscular Atrophy

phase 3 small molecule active

1 trial
Saline Solution Basi 9 mg/ml solution for infusion, Felzartamab

Biogen

Kidney Transplant Recipients with Late Antibody-Mediated Rejection

phase 3 small molecule active

1 trial
TECFIDERA

Biogen

Relapsing-Remitting Multiple Sclerosis

phase 3 small molecule active

1 trial
Tofersen

Biogen

Amyotrophic Lateral Sclerosis

phase 3 small molecule completed

1 trial
dimethyl fumarate

Biogen

Relapsing-Remitting Multiple Sclerosis

phase 3 small molecule completed

1 trial
Felzartamab

Biogen

Immunoglobulin A (IgA) Nephropathy

phase 2 small molecule completed

1 trial
Felzartamab, Saline Solution Basi 9 mg/ml solution for infusion

Biogen

Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants

phase 2 small molecule active

1 trial
Matching Placebo tablets without active substance, BIIB122

Biogen

Parkinson's Disease

phase 2 small molecule active

1 trial
X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza)

Biogen

Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.

phase 2 small molecule active

1 trial
BIIB115

Biogen

Healthy Volunteer

phase 1 small molecule active

1 trial
BiiB115 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of BIIB115 drug product minus the active ingredient, BIIB115

Biogen

Spinal muscular atrophy

phase 1 small molecule active

1 trial
Placebo oral capsule

Biogen

Healthy

phase 1 small molecule completed

1 trial
Spinraza 12 mg solution for injection

Biogen

Spinal Muscular Atrophy

phase 1 small molecule active

1 trial
Dimethyl fumarate

Biogen

Multiple Sclerosis

approved small molecule completed

1 trial
Spinraza 12 mg solution for injection

Biogen

Spinal Muscular Atrophy

approved small molecule active

1 trial

Frequently asked questions

How many pipeline programs does Biogen have?

31 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Quick answer

0.9% Saline, PARACETAMOL , Felzartamab, CETIRIZINE , LORATADINE , FAMOTIDINE , DIPHENHYDRAMINE , LEVOCETIRIZINE , DESLORATADINE , FEXOFENADINE , METHYLPREDNISOLONE

BG00012

BIIB019 (Daclizumab)

BIIB059

BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient

BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient

BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient.

BIIB067, PL1, Solution for injection, Intrathecal use. [Placebo]

BIIB111

Bardoxolone methyl

Felzartamab

Hard capsules, BIIB141

Placebo

Plegridy 125 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5ml solution for injection in pre-filled pen., Plegridy 63 micrograms+94 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5 ml solution for injection.

SPINRAZA 28 mg, SPINRAZA 50 mg

SPINRAZA 50 mg, SPINRAZA 28 mg

Saline Solution Basi 9 mg/ml solution for infusion, Felzartamab

TECFIDERA

Tofersen

dimethyl fumarate

Felzartamab

Felzartamab, Saline Solution Basi 9 mg/ml solution for infusion

Matching Placebo tablets without active substance, BIIB122

X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza)

BIIB115

BiiB115 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of BIIB115 drug product minus the active ingredient, BIIB115

Placebo oral capsule

Spinraza 12 mg solution for injection

Dimethyl fumarate

Spinraza 12 mg solution for injection

Frequently asked questions

Stay Ahead in Pharma